Restore Mind Medicine

ISS Accepts the Company's Word Vallone's "Outlier" Director Compensation Reality: ISS acknowledges that Vallone and Krebs received outlier compensation as directors. X ISS took MindMed's word that Vallone and Krebs offered "critical assistance" which resulted in the compensation committee approving this compensation. This ignores that Vallone is the chair of the compensation committee. ISS Accepts Company's Arguments on Phase llb Without Any Analysis Reality: X ISS does not address our arguments regarding the serious issues afflicting the Phase Ilb trial. Rather, ISS accepts Company's reasoning to pursue an unnecessary Phase IIb trial without any examination of the facts. ISS further hangs its hat on the Greenleaf report without acknowledging our various arguments about why the Phase IIb is flawed. ISS Accepts That NEO's Met Corporate Goals Reality: ✔ Ignores that many of MindMed's goals were simply following the law or were unmet. Ignores that NEO compensation does not have any real performance requirements. Ignores that the primary reason for executive compensation going down was due to share price decline. ISS Accepts Compass as One of MindMed's "Closest Peers" Reality: Company Mind Medicine Compass Pathways Seelos Source: Company's SEC Filings, Company SEDI Filings, Data From Refinitiv, Clinicaltrials.gov. See ISS Report Current Trials 2 5 2 Expected Enrollment 252 1128 399 G&A Expenses (FY2022) 30M 45M 12M 7

View entire presentation